
Bayer announces more changes at the top
pharmafile | June 6, 2014 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |ย ย Bayer, Dieter Weinand, Otsuka, dekkers, healthcareย
US-based president at Japanese drugmaker Otsuka, Dieter Weinand, is to join Bayer Healthcare Pharmaceuticals as the new head of its prescription drugs unit.
The news follows major changes occurring at the German pharma giant, notably chief executive of Bayer group Marijn Dekkers and his decision to step down at the end of 2016, but also confirmation that Andrea Fibig, the current president of its Bayer Healthcare division, is to leave to become chief executive of International Flavors & Fragrances (IFF).
Olivier Brandicourt who is chief executive of Bayerโs HealthCare pharma unit, says: โWe welcome Dieter Weinand to our management team. Based on his extensive commercial experience in the pharmaceutical industry, Dieter Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio.โโจโจ
Weinand has more than 25 years of experience in various commercial operative and strategic executive roles in pharma. He has been responsible for different markets according to the firm, such as Asia-Pacific, Europe, Middle East, Africa, Latin America and the US.
Prior to taking up his role, German-born Weinand has worked at companies including Pfizer and Bristol-Myers Squibb on the marketing of products in different therapeutic areas: such as cardiology, oncology, pulmonology, dermatology, immunology and inflammation.
Bayer now has over two years to decide who will succeed Dekkers in the top job for the group, but for the time being Werner Baumann will take on the role of chief strategy and portfolio officer, to โensure continuity in key aspects of Bayerโs future developmentโ.
Replacing Baumann as chief financial officer will be Johannes Dietsch, who is based in Shanghai and will assume Bayerโs CFO role there in China.
Brett Wells
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

ADHD coach and breathwork experts to run workshop for ADHD management
ADHD coach John Harrington and breathwork facilitator Martin OโToole will collaborate on ‘Breathwork for ADHD …

Third application for Orionโs prostate cancer drug submitted by partner Bayer
Finnishย pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …






